PCNA and neoplasm: In support, endpoint tumour weights were also comparable between the treatment arms (Supplementary Figure S5) and quantitation of IHC to detect the apoptotic marker Cleaved caspase-3 (CC3) and the proliferation marker PCNA revealed that the number of PCNA and CC3 positive cells is unaltered in CU-PC01 tumours in response to enzalutamide or docetaxel treatment (Figure 6B–D).